Patents Examined by Mark V Stevens
  • Patent number: 11896715
    Abstract: The present invention relates to an in-vivo bulking agent which can be used as a medicinal agent for prevention or treatment of at least one disease selected from the group consisting of urinary incontinence, fecal incontinence, and gastroesophageal reflux or as a filler for use in a plastic surgery procedure, and to a preparation method therefor. The in-vivo bulking agent can exhibit a bulking effect when injected into the body and particularly, is highly biocompatible because a first composition in which silicone particles are coated with a zwitterionic polymer having a surfactant property is introduced into a second composition, whereby the bulking agent can inhibit inflammatory reactions in vivo.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: February 13, 2024
    Assignee: KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
    Inventors: Kwang Dae Hong, Jihun Seo, Joon Bum Lee
  • Patent number: 11896722
    Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.
    Type: Grant
    Filed: January 5, 2022
    Date of Patent: February 13, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Ricardo Alberto Vargas Rincon, Joseph Reiz
  • Patent number: 11883538
    Abstract: The present invention relates to sustained release tablet comprising micronized tolcapone, a release retardant and a binder, to said tablet for use in the prevention and/or treatment of a transthyretin-associated amyloidosis, to a method for the prevention and/or treatment of a transthyretin-associated amyloidosis comprising administering to a subject in need thereof an effective amount of said tablet, to pharmaceutical composition in the form of said tablet which is used in the prevention and/or treatment of a transthyretin-associated amyloidosis and to a process for the manufacture of said tablet.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: January 30, 2024
    Assignee: Som Innovation Biotech, S.L.
    Inventors: Anna Nardi Ricart, Josep María Suñé Negre, Núria Reig Bolaño, Raúl Insa Boronat, Oscar Huertas Gambín, Santiago Esteva Gras, Gal⋅Ia Pericot Mohr
  • Patent number: 11883469
    Abstract: A polyacrylonitrile (PANi) based pharmaceutical composition providing a porous implant for use in treating spinal cord trauma and/or spinal cord injury. Particularly a pharmaceutical composition including polyacrylonitrile (PANi) and/or elastin (E) and/or collagen (C) to form a PANi-E and/or PANi-C and/or a PANi-EC polymer network. Particularly, a pharmaceutical composition including polyacrylonitrile (PANi), elastin (E), and collagen (C) together forming a polyacrylonitrile (PANi), elastin (E), collagen (C) polymer network (PANi-E-C), wherein the polyacrylonitrile (PANi) may be crosslinked to form a crosslinked interpenetrating polyacrylonitrile (PANi), elastin (E) and collagen (C) polymer network (xpi-PANi-E-C), and wherein secondary protein structures of elastin (E) and collagen (C) reorientate. The disclosure extends to use of the pharmaceutical composition in the treatment of spinal cord trauma and/or spinal cord injury.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: January 30, 2024
    Assignee: UNIVERSITY OF THE WITWATERSRAND, JOHANNESBURG
    Inventors: Pradeep Kumar, Viness Pillay, Yahya Essop Choonara, Girish Modi
  • Patent number: 11883562
    Abstract: The present disclosure relates to bioactive hydrogels derived from human blood plasma. More particularly, the disclosure relates to multifunctional materials for cell encapsulation, cell culture platforms, medical treatment apparatus and methods, more particularly, hydrogels derived from human blood components and technologies for use of such materials in research, biomedical treatment, biotech and pharmaceutical industry. The disclosure further relates to 3D printable scaffolds, sponges, foams, fibers, particles, capsules, membranes and injectable systems comprising said hydrogel. Additionally, this disclosure allows for the controlled placement of biologically active components that may be delivered by the hydrogel compositions.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: January 30, 2024
    Assignee: UNIVERSIDADE DE AVEIRO
    Inventors: João Filipe Colardelle Da Luz Mano, Catarina De Almeida Custódio, Sara Catarina Nunes Da Silva Santos
  • Patent number: 11872218
    Abstract: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a mixture of the vehicle and the non-volatile solvent, and which composition is effective in treating a disorder of the nail or nail bed.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: January 16, 2024
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Gareth Winckle, Gregory T. Fieldson
  • Patent number: 11872232
    Abstract: Provided herein include caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. Also provided are methods for the production of caffeinated, partially decaffeinated, and decaffeinated paraxanthine beverages, coffees and paraxanthine coffee beverages. In some embodiments, disclosed compositions may provide consumers with increased alertness and wakefulness, while preventing side effects commonly associated with caffeinated drinks.
    Type: Grant
    Filed: April 12, 2023
    Date of Patent: January 16, 2024
    Assignee: RAREBIRD, INC.
    Inventors: Jeffrey Dietrich, Maddison Kylie Gurrola, Amanda Jacklyn Grace Sinrod, Edwin Yparraguirre Palang
  • Patent number: 11866385
    Abstract: A coating composition comprising an adduct formed by chemical reaction of a monomer containing poly-thiol with a monomer containing one or more unsaturated carbon-carbon bond; more particularly relates to coated agrochemical compositions coated with said coating composition.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: January 9, 2024
    Assignee: EVERRIS INTERNATIONAL B.V.
    Inventors: Evgeniy Tkalya, Ronald Petrus Johannes Gosens, Susan Tine Kathelyne Sijstermans, Michael Ernest Josephina Hendriks, Martin Anna Fransiscus Jacobus. Marx, Karina Rabe, Gerardus Jacobus Joseph Out
  • Patent number: 11850298
    Abstract: In some embodiments, an anti-aging composition includes hyaluronic acid, at least one anti-aging peptide, at least one skin penetration enhancer, and water. In some embodiments, an anti-aging composition includes hyaluronic acid, at least one anti-aging peptide, at least one tensing polymer, and water. An anti-aging product includes a skin mask patch and an anti-aging composition loaded into the skin mask patch. A method of forming an anti-aging product includes forming an anti-aging composition and loading the anti-aging composition into a skin mask patch.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: December 26, 2023
    Assignee: L'OREAL
    Inventors: Paula Cziryak, Valérie Robert
  • Patent number: 11844796
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: December 19, 2023
    Assignee: CLEXIO BIOSCIENCES LTD.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Manuel A. Vega Zepeda
  • Patent number: 11844854
    Abstract: The present application relates to perfume raw materials, perfumes, perfume delivery systems and consumer products comprising such perfume raw materials, perfumes and/or such perfume delivery systems, as well as processes for making and using such perfume raw materials, perfume delivery systems and consumer products. The perfumes disclosed herein expand the perfume communities' options.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: December 19, 2023
    Assignee: The Procter & Gamble Company
    Inventors: Jonathan Robert Cetti, Zerlina Guzdar Dubois, Virginia Tzung-Hwei Hutchins, Michael Wayne Kinsey, Christine Marie Readnour, Christelle Marie Sandrine Bonnet, Lynette Anne Makins Holland, Fabienne Pastor, Jose Maria Velazquez Mendoza, Jonathan Richard Stonehouse, William Eoghan Staite
  • Patent number: 11839628
    Abstract: A three component composition for use in the treatment of an autoimmune disease where the first component comprises a bimodal synthetic carbon particle mixture; the second component comprises a bimodal synthetic carbon particle mixture and an anion exchange resin and the third component comprises a bimodal synthetic carbon particle mixture and a cation exchange resin.
    Type: Grant
    Filed: March 26, 2021
    Date of Patent: December 12, 2023
    Assignee: Immutrix Therapeutics, Inc.
    Inventors: Carol A Rae, Jan Simoni, Grace Simoni, John F. Moeller
  • Patent number: 11839682
    Abstract: A method for obtaining a culture supernatant form microalgae is provided, particularly wherein the culture supernatant is IMAC-enriched microalga culture supernatant and to an IMAC-enriched microalga culture supernatant obtained by the method of the invention. Also provided is a combination having a microalgal culture supernatant and a growth factor and to a cell culture media; a cosmetic composition and pharmaceutical composition and uses thereof.
    Type: Grant
    Filed: May 8, 2019
    Date of Patent: December 12, 2023
    Assignee: GAT BIOSCIENCES, S.L.
    Inventors: Olga Durany Turk, Jordi Segura De Yebra, Jaume Mercade Roca, Maria Teresa Lopez Cerro, Cristina Lopez Paz
  • Patent number: 11839487
    Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.
    Type: Grant
    Filed: June 24, 2022
    Date of Patent: December 12, 2023
    Assignee: EYENOVIA, INC.
    Inventors: Bernard L. Ballou, Jr., Mark Packer, Russell John Mumper, Tsontcho Ianchulev
  • Patent number: 11840552
    Abstract: The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: December 12, 2023
    Assignee: RENIBUS THERAPEUTICS, INC.
    Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem, Richard A. Zager
  • Patent number: 11834471
    Abstract: The present invention involves a novel aqueous iron composition. The aqueous iron composition includes iron sucrose and bicarbonate. The aqueous iron composition of the invention exhibits enhanced renal protective effects relative to conventional iron sucrose compositions.
    Type: Grant
    Filed: November 2, 2022
    Date of Patent: December 5, 2023
    Assignee: Renibus Therapeutics, Inc.
    Inventors: Donald Jeffrey Keyser, Alvaro F. Guillem, Richard A. Zager
  • Patent number: 11826382
    Abstract: Method and composition for treating or preventing a respiratory illness. The method includes administering at least one dose of a pharmaceutically acceptable fluid having a pH less than 3.0 into contact with at least one region of the respiratory tract present in a patient in need thereof. Respiratory illness that can be treated include COVID-19.
    Type: Grant
    Filed: December 10, 2021
    Date of Patent: November 28, 2023
    Assignee: Tygrus, LLC
    Inventors: Paul Bundschuh, Lawrence Carlson, Shawn Dolan, Andrew M. Yaksic
  • Patent number: 11826456
    Abstract: The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of one or more of Butyrospermum parkii (shea butter), PEG-50 shea butter, glycerin, Helianthus annuus (sunflower) seed oil, Prunus armeniaca (apricot) kernel oil, acrylates copolymer, sodium lauryl sulfate, lauramidopropyl betaine, sodium methyl cocoyl taurate, glycerin, and polyquaternium-7.
    Type: Grant
    Filed: January 6, 2022
    Date of Patent: November 28, 2023
    Assignee: MARY KAY INC.
    Inventors: Michael Frushour, Lisha Vanpelt, Kim Wilson, Geetha Kalahasti, Lee Vickers
  • Patent number: 11820729
    Abstract: Provided are compounds described by the Formula I: wherein: R1 is a linear or branched, saturated or unsaturated aliphatic group having from 5 to 22 carbon atoms; R2 is selected from the group consisting of the functional groups: —NH2; and salts thereof; n is from 0 to 4; and R3 is a linear or branched, saturated or unsaturated aliphatic group having from 1 to 6 carbon atoms. Also provided are compositions comprising, and methods of use of, the compounds of the present invention.
    Type: Grant
    Filed: June 3, 2021
    Date of Patent: November 21, 2023
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Robert J. Gambogi, Anthony R. Geonnotti, III, Michael C. Giano, Latrisha Petersen
  • Patent number: 11806348
    Abstract: The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.
    Type: Grant
    Filed: January 24, 2022
    Date of Patent: November 7, 2023
    Assignee: INTRA-CELLULAR THERAPIES, INC.
    Inventors: Peng Li, Robert Davis